In this context, Mack PC et al. showed that EGFR ctDNA clearance after 60 days of EGFR-TKI and anti-EGFR-MoAb combination regimen correlated with substantial improvement in PFS and OS in a cohort of advanced NSCLC underwent a 73-gene blood-based NGS panel suggesting a role of LB in determining novel pharmacodynamic predictive biomarkers of response/resistance to targeted agents [236]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.